Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Joseph P. Lyssikatos Sells 12,500 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph P. Lyssikatos sold 12,500 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $21.40, for a total transaction of $267,500.00. Following the completion of the sale, the insider now directly owns 965,188 shares of the company's stock, valued at approximately $20,655,023.20. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Enliven Therapeutics Trading Down 4.3%

Shares of Enliven Therapeutics stock traded down $0.92 during trading on Friday, reaching $20.61. The company's stock had a trading volume of 554,110 shares, compared to its average volume of 347,372. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.03. The stock has a 50-day moving average price of $19.24 and a two-hundred day moving average price of $20.49. The stock has a market capitalization of $1.01 billion, a P/E ratio of -10.73 and a beta of 0.79.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. The Goldman Sachs Group initiated coverage on Enliven Therapeutics in a research note on Monday, June 16th. They set a "buy" rating and a $37.00 target price for the company. HC Wainwright increased their target price on Enliven Therapeutics from $39.00 to $40.00 and gave the company a "buy" rating in a report on Thursday, May 15th. Jones Trading lowered their price objective on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Finally, Robert W. Baird boosted their target price on Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, June 16th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $39.60.

Institutional Trading of Enliven Therapeutics

Large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its holdings in Enliven Therapeutics by 2.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company's stock worth $5,892,000 after buying an additional 6,611 shares during the period. Swiss National Bank grew its holdings in shares of Enliven Therapeutics by 13.9% in the 4th quarter. Swiss National Bank now owns 41,873 shares of the company's stock valued at $942,000 after acquiring an additional 5,100 shares in the last quarter. Intech Investment Management LLC bought a new position in Enliven Therapeutics in the fourth quarter valued at approximately $367,000. KLP Kapitalforvaltning AS acquired a new position in Enliven Therapeutics during the fourth quarter worth $97,000. Finally, Vanguard Group Inc. increased its stake in shares of Enliven Therapeutics by 2.9% during the 4th quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock worth $44,452,000 after purchasing an additional 55,283 shares during the last quarter. Institutional investors own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.